{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:28:09Z","timestamp":1791080889798,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,11,16]],"date-time":"2012-11-16T00:00:00Z","timestamp":1353024000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1471-230x-12-162","type":"journal-article","created":{"date-parts":[[2012,11,16]],"date-time":"2012-11-16T10:14:16Z","timestamp":1353060856000},"source":"Crossref","is-referenced-by-count":19,"title":["HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b"],"prefix":"10.1186","volume":"12","author":[{"name":"and for the CLEO Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano M","family":"Pellicelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Stroffolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ettore","family":"Mazzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Mecenate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Monarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Picardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elena","family":"Bonaventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mastropietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Vignally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaldo","family":"Andreoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Marignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"D\u2019Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Miglioresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Nosotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Mitidieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto Vespasiani","family":"Gentilucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Puoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Barbaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Barlattani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Furlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Barbarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,11,16]]},"reference":[{"key":"826_CR1","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","volume":"360","author":"JG McHutchison","year":"2009","unstructured":"McHutchison JG, Everson GT, Gordon SC, et al: PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009, 360: 1827-1838. 10.1056\/NEJMoa0806104.","journal-title":"N Engl J Med"},{"key":"826_CR2","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(10)60934-8","volume":"376","author":"PY Kwo","year":"2010","unstructured":"Kwo PY, Lawitz EJ, McCone J, et al: SPRINT-1 investigators. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010, 376: 705-716. 10.1016\/S0140-6736(10)60934-8.","journal-title":"Lancet"},{"key":"826_CR3","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"MW Fried","year":"2002","unstructured":"Fried MW, Shiffman ML, Reddy K, et al: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002, 347: 975-982. 10.1056\/NEJMoa020047.","journal-title":"N Engl J Med"},{"key":"826_CR4","doi-asserted-by":"publisher","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","volume":"140","author":"SJ Hadziyannis","year":"2004","unstructured":"Hadziyannis SJ, Sette H, Morgan TR, et al: PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004, 140: 346-355.","journal-title":"Ann Intern Med"},{"key":"826_CR5","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jhep.2010.04.024","volume":"53","author":"WS Cheng","year":"2010","unstructured":"Cheng WS, Roberts SK, McCaughan G: Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. J Hepatol. 2010, 53: 616-623. 10.1016\/j.jhep.2010.04.024.","journal-title":"J Hepatol"},{"key":"826_CR6","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.jhep.2004.05.012","volume":"41","author":"S Bruno","year":"2004","unstructured":"Bruno S, Camm\u00e0 C, Di Marco V, et al: Peginterferon alfa-2b plus ribavirin for na\u00efve patients with genotype 1 chronic hepatitis C: a randomized controlled trial. Hepatol. 2004, 41: 474-481. 10.1016\/j.jhep.2004.05.012.","journal-title":"Hepatol"},{"issue":"48","key":"826_CR7","doi-asserted-by":"publisher","first-page":"S311","DOI":"10.1016\/S0168-8278(08)60831-4","volume":"2","author":"M Rizzetto","year":"2008","unstructured":"Rizzetto M, Colombo M, Ascione A, et al: Effectiveness of hepatitis C virus treatment in real life practice: a prospective observational multicenter study in Italy (PROBE). J Hepatol. 2008, 2 (48): S311-","journal-title":"J Hepatol"},{"key":"826_CR8","first-page":"2029","volume":"81","author":"F Legrand-Abravanel","year":"2009","unstructured":"Legrand-Abravanel F, Colson P, Leguillou-Guillemette L, et al: Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. J MedVirol. 2009, 81: 2029-2035.","journal-title":"J MedVirol"},{"key":"826_CR9","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/jmv.21976","volume":"83","author":"F Nicot","year":"2011","unstructured":"Nicot F, Alric L, Barange K, et al: Influence of genotype 1 subtypes on the virus response to Peg interferon alpha-2a plus ribavirin therapy. J Med Virol. 2011, 83: 437-444. 10.1002\/jmv.21976.","journal-title":"J Med Virol"},{"key":"826_CR10","doi-asserted-by":"publisher","first-page":"s12","DOI":"10.1016\/S1590-8658(12)60036-X","volume":"44S","author":"F Rosina","year":"2012","unstructured":"Rosina F, Tosti ME, Borghesio E, et al: PEG-IFN for chronic hepatitis C in clinical practice: the prospective phase of the AIFA study. Dig Liv Dis. 2012, 44S: s12-","journal-title":"Dig Liv Dis"},{"key":"826_CR11","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/hep.1840010511","volume":"1","author":"RG Knodell","year":"1981","unstructured":"Knodell RG, Ishak KG, Black WC, et al: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981, 1: 431-435. 10.1002\/hep.1840010511.","journal-title":"Hepatology"},{"key":"826_CR12","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1053\/j.gastro.2005.11.010","volume":"130","author":"JL Dienstag","year":"2006","unstructured":"Dienstag JL, McHutchinson J: American Gastroenterological association technical review on the management of hepatitis C. Gastroenterology. 2006, 130: 231-264. 10.1053\/j.gastro.2005.11.010.","journal-title":"Gastroenterology"},{"key":"826_CR13","doi-asserted-by":"publisher","first-page":"634","DOI":"10.7326\/0003-4819-125-8-199610150-00002","volume":"125","author":"NN Zein","year":"1996","unstructured":"Zein NN, Rakela EL, Krawitt KR, Reddy KR, Tominaga T, Persing DH: Hepatitis C virus genotypes in United States: epidemiology, pathogenicity, and response to interferon therapy. Ann Intern Med. 1996, 125: 634-639.","journal-title":"Ann Intern Med"},{"key":"826_CR14","first-page":"223","volume":"13","author":"NN Zein","year":"2000","unstructured":"Zein NN: Clinical significance of hepatitis C virus genotypes. ClinMicrobiol Rev. 2000, 13: 223-235.","journal-title":"ClinMicrobiol Rev"},{"key":"826_CR15","first-page":"223","volume":"73","author":"E Nevens","year":"2010","unstructured":"Nevens E, Van Vlierberghe H, D\u2019Heygere E, et al: BERNAR-1 Study Group. A randomized open label, multicenter studyevaluating the efficacy of peginterferon alfa 2a, in combination with ribavirin, in na\u00efve and relapsed chronic hepatitis C patient. Acta Gastroenterol Belg. 2010, 73: 223-228.","journal-title":"Acta Gastroenterol Belg"},{"key":"826_CR16","first-page":"832","volume":"22","author":"JW Yu","year":"2007","unstructured":"Yu JW, Wang GQ, Sun LJ, Li XG, Li SC: Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J GastroenterolHepatol. 2007, 22: 832-836.","journal-title":"J GastroenterolHepatol"},{"key":"826_CR17","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1053\/j.gastro.2009.11.055","volume":"138","author":"C Sarrazin","year":"2010","unstructured":"Sarrazin C, Zeuzem S: Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology. 2010, 138: 447-462. 10.1053\/j.gastro.2009.11.055.","journal-title":"Gastroenterology"},{"key":"826_CR18","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMoa0808010","volume":"361","author":"JG McHutchison","year":"2009","unstructured":"McHutchison JG, Lawitz EJ, Shiffman ML, et al: Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009, 361: 580-593. 10.1056\/NEJMoa0808010.","journal-title":"N Engl J Med"},{"key":"826_CR19","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1053\/j.gastro.2009.10.005","volume":"138","author":"A Ascione","year":"2010","unstructured":"Ascione A, De Luca M, Tartaglione MT, et al: Peginterferon alfa-2a plus ribavirin is nore effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology. 2010, 138: 116-122. 10.1053\/j.gastro.2009.10.005.","journal-title":"Gastroenterology"},{"key":"826_CR20","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1053\/j.gastro.2009.08.071","volume":"138","author":"MG Rumi","year":"2010","unstructured":"Rumi MG, Aghemo A, Prati GM, et al: Randomized study of peginterferon alfa2a plus ribavirin vs peginterferon alfa2b plus ribavirin in chronic hepatitis C. Gastroenterology. 2010, 138: 108-115. 10.1053\/j.gastro.2009.08.071.","journal-title":"Gastroenterology"},{"key":"826_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1365-2893.2011.01525.x","volume":"19","author":"MG Rumi","year":"2012","unstructured":"Rumi MG, Aghemo A, Prati GM: Comparative trials of peginterferon alfa-2a and peginterferon alfa-2b for chronic hepatitis C. J Viral Hepatol. 2012, 19: 37-41.","journal-title":"J Viral Hepatol"},{"issue":"139","key":"826_CR22","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1053\/j.gastro.2010.04.013","volume":"2010","author":"AJ Thompson","year":"2010","unstructured":"Thompson AJ, Muir AJ, Sulkowski MS, et al: Interleukin-28B polymorphism improves viral kinetics and is the strongestpretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010, 2010 (139): 120-129.","journal-title":"Gastroenterology"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-230X-12-162\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-230X-12-162.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-230X-12-162","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-230X-12-162.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T03:35:05Z","timestamp":1548128105000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/1471-230X-12-162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,16]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["826"],"URL":"https:\/\/doi.org\/10.1186\/1471-230x-12-162","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,16]]},"article-number":"162"}}